SEARCH:
Print

Clinical Trials

Bavarian Nordic and its partners conduct clinical studies of its vaccine candidates to evaluate their safety and efficacy.

Clinical studies that are actively enrolling patients or are planned are detailed below.

Ongoing or planned trials

Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Location: USA
Read more: NCT03628716
Phase 2 Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer
Location: USA
Read more: NCT03547999
A Phase 1/2 Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma
Location: USA
Read more: NCT03376659

Ongoing or planned trials

Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma
Location: USA
Read more: NCT03595228
Phase 1/2 Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1)
Location: USA
Read more: NCT03493945

Ongoing or planned trials

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Location: USA
Read more: NCT03532217
PROSTVAC in Patients With Biochemically Recurrent Prostate Cancer
Location: USA
Read more: NCT02649439
Phase 2 Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Location: USA
Read more: NCT03315871
Phase 2 Study of Adjuvant PROSTVAC in Subjects at High Risk for Relapse After Radical Prostatectomy
Location: USA
Read more: NCT02772562
Phase 1/2 Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Location: USA
Read more: NCT02933255
Phase 2 Study of PROSTVAC and Docetaxel for Metastatic Castration Sensitive Prostate Cancer
Location: USA
Read more: NCT02649855